Guggenheim raised the firm’s price target on Neurocrine (NBIX) to $165 from $155 and keeps a Buy rating on the shares. Ingrezza Q1 sales at about $545M came in about 1% below consensus of $552M, but “well above buyside expectations,” the analyst tells investors in a post-earnings note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine price target raised to $183 from $179 at BofA
- Cautious Outlook for Neurocrine Amid Cinecerfont Launch Success and Earnings Challenges
- Neurocrine price target raised to $160 from $158 at Canaccord
- Neurocrine price target lowered to $154 from $160 at Piper Sandler
- Promising Growth Prospects for Neurocrine: Buy Rating Affirmed by Anupam Rama